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Treatment options for metastatic urothelial bladder can-
cer (UBC) are limited. Mutational complexity is known
to be high in UBC and may correlate with increased
immunogenicity. MPDL3280A, a human PD-L1 mono-
clonal antibody containing an engineered Fc-domain
designed to promote a Th1-driven response, has demon-
strated a RECIST response rate of 43% in diagnostically
selected, pretreated patients with UBC. A total of
68 patients (67 with efficacy evaluable) were enrolled in
the UBC cohort of the Phase I study; 45% were PD-L1
IHC diagnostic positive as defined by expression of PD-
L1 on ≥ 5% of tumor-infiltrating immune cells. In the
prescreened UBC population, the prevalence of PD-L1-
positive patients was 27%.
Comprehensive gene expression analyses of UBC
tumors were conducted to interrogate the tumor
immune microenvironment in PD-L1-positive tumors
and to identify potential mechanisms associated with
response or resistance to MPDL3280A. In this study,
PD-L1-positive tumors exhibited a high prevalence of
gene expression markers associated with T-effector cells
(Teff), including perforin, IFNg, CD8A, granzyme B,
granzyme A and EOMES. Additionally, a low baseline
signature of genes associated with myeloid cell markers,
including IL1B and IL8, appeared to be statistically sig-
nificantly associated (P<0.01) with MPDL3280A
response, suggesting a potential role for myeloid biology
in resistance to MPDL3280A treatment in UBC.
Tumor burden markers, including CA-125, CA19-9
and human chorionic gonadotropin (HCG), have been
associated with chemotherapy response markers in
UBC. A marked decrease in these markers, including
CEA, CA19-9, CA-125 and HCG, was observed with
MPDL3280A response after 1 treatment cycle, poten-
tially enabling an on-treatment monitoring alternative
for response to therapy. Similarly, evaluation of cyto-
kines on treatment identified markers, including IL-6
and IL-10, elevated as early as Cycle 2 only in patients
without response to MPDL3280A. These circulating
cytokines and tumor-associated gene signatures suggest
potential mechanisms associated with resistance and
response to MPDL3280A in UBC and provide a ratio-
nale for informed combination strategies to further
improve treatment benefit in this indication.
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